sorafenib has been researched along with osu 03012 in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (osu 03012) | Trials (osu 03012) | Recent Studies (post-2010) (osu 03012) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 85 | 0 | 55 |
| Protein | Taxonomy | sorafenib (IC50) | osu 03012 (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
| Albers, T; Booth, L; Bottaro, D; Chen, CS; Dent, P; Ecroyd, H; Lebedyeva, IO; Proniuk, S; Roberts, JL; Shuch, B; Tavallai, M; Wang, D; Zukiwski, A | 1 |
2 other study(ies) available for sorafenib and osu 03012
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Indazoles; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Sorafenib; Sulfonamides | 2016 |